Preoperative immunochemotherapy with PSK for Stage II/III gastric and colorectal cancer to evaluate anti-tumor effect and transition of PSKinto tumor

Preoperative immunochemotherapy with PSK for Stage II/III gastric and colorectal cancer to evaluate anti-tumor effect and transition of PSKinto tumor - Preoperative immunochemotherapy with PSK for Stage II/III gastric and colorectal cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005286

Enrollment

Registered

2011-03-22

Start date

2010-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric and colorectal cancer with clinical stage II/III

Interventions

TS-1 chemotherapy alone group TS-1 with PSK group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with clinically diagnosed as Stage II/III Gastric and colorectal cancer scheduled for surgical resection 2. Age between 20 and 80 3. No pretreatemnt for cancer 4. No redundant cancer 5. Patients who have retained well-torelated function of major organs including liver kidney and bone marrow 6. Performance Status 0~2 7, No severe coexisting desease 8. Informed and concent by written documant

Exclusion criteria

Exclusion criteria: 1. Patients with active gastro-intestinal bleeding 2. Patients with massive ascites 3. Patients with active infection desease and ileus 4. Pregnant women 5. Patients with uncontrolled diabetes 6. Patients with ischemic heart desease 7. Patients with uncontrolled psychiatric disorder 8. Required administration of continual steroids 9. Histry of severe allergic desease 10. Pateints assesed inadequate case by principal investigator

Design outcomes

Primary

Measure	Time frame
To examine transition of PSK and induce infiltration of cytotoxic T lymphocytes into primary tumor	—

Countries

Japan

Contacts

Public ContactHiroaki Tanaka

Osaka City Osaka CIty University Graduate School Surgical Oncology

hiroakitan@med.osaka-cu.ac.jp06-6645-3838

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026